ITOS News and Press, iTeos Therapeutics Inc. From 08/23/23

2023-08-23 08:47:02 ET VCI Global ( VCIG ) +61% after announces visionary collaboration with Microsoft Azure OpenAI . iTeos Therapeutics ( ITOS ) +37% in reaction as Roche send anti-TIGIT developers higher after mistakenly-released cancer drug data . Arcus ...

2023-08-23 07:31:22 ET More on Roche Roche drives rival anti-TIGIT developers higher after cancer drug data Roche, With Ocrevus And Fenebrutinib Advancement, Should Be Top MS Contender Roche, Alnylam in pact for blood pressure candidate Roivant report...

2023-08-08 08:02:19 ET iTeos Therapeutics press release ( NASDAQ: ITOS ): Q2 GAAP EPS of -$0.96. The company’s cash, cash equivalents, and investments position was $677.5 million as of June 30, 2023, as compared to $791.9 million as of June 30, 2022. For furth...

– Preparation underway with GSK for Phase 3 registrational studies evaluating belrestotug and dostarlimab combination – Initiated enrollment in Phase 1 trial of EOS-984, a first-in-class program targeting a new mechanism of action in the adenosine pathway &...

2023-07-10 04:56:16 ET Summary The new July 2023 selections are the current top positive/negative forensic stocks based on combined scores from four different forensic algorithms. Both the 2022 January Positive Forensic portfolio beat the S&P 500 by +6.59% and the Negative For...

2023-06-08 12:15:22 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – June 8, 2023 – USA News Group –  By utilizing newly developed novel mechanisms, biotech researchers and scientists are making strides in the battle aga...

2023-06-04 10:04:13 ET Summary Today, we circle back on small oncology concern iTeos Therapeutics, Inc. for the first time since last July. The company is advancing its two primary compounds in its pipeline and has a potentially lucrative partnership with GlaxoSmithKline. The ...

2023-05-10 08:58:59 ET iTeos Therapeutics press release ( NASDAQ: ITOS ): Q1 GAAP EPS of -$0.44. The company’s cash, cash equivalents, and investments position was $706.6 million as of March 31, 2023, as compared to $824.0 million as of March 31, 2022. Research ...

– Belrestotug, formerly EOS-448, is advancing through multiple late-stage clinical trials including both doublet and triplet regimens – First-in-class program targeting a new mechanism of action in the adenosine pathway, EOS-984, is expected to enter cli...

- 10 ongoing or planned clinical trials throughout 2023 to advance both differentiated clinical programs, anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and adenosine A2A receptor antagonist inupadenant - EOS-984, a first-in-class program targeting a new mechanism of action in the a...